4 results
Prazosin for the treatment of Obsessive Compulsive Disorder:
An open label, fixed dose add-on study.
To determine whether the addition of the *1 adrenoreceptor antagonist prazosin to SSRI is useful for patients with OCD who do not respond to SRI monotherapy.
The primary objective of this study is to enable continued treatment with the study drug sonlicromanol for patients who have completed study KH176-202 and to investigate the safety and tolerability of sonlicromanol over an 12 months treatment period…
Primary objective(s): To assess the effect of LysaKare® administration on serum potassium concentration in GEP-NET patients eligible for Lutathera® treatmentSecondary objective(s): To confirm the safety profile of LysaKare® infusion in GEP-NET…
Primary Objective:To evaluate the effect of sonlicromanol on motor symptom severity in children with genetically confirmed mitochondrial disease affecting oxidative phosphorylation during a 6 month treatment period (GMFM).